Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01171014
Other study ID # #08-SPUS-o6-FON-01
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received July 26, 2010
Last updated July 27, 2010
Start date June 2009
Est. completion date December 2009

Study information

Verified date July 2010
Source Fonterra Research Centre
Contact n/a
Is FDA regulated No
Health authority New Zealand: Food Safety Authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to investigate the dose response effect of Bifidobacterium lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 2009
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria:

- healthy males and females aged 25 to 65 years

- stool type 2-4 on the Bristol Stool Chart

- 1 to 3 bowel movements per week

Exclusion Criteria:

- use of any probiotic product intended to improve gastrointestinal function within the 2 weeks preceding study entry

- major chronic and uncontrolled systemic medical conditions

- severe gastrointestinal conditions known to prolong CTT

- lactose intolerance

- chronic diarrhea

- gastric bypass surgery or lap band insertion for weight loss

- regular laxative use

- pregnant or breast-feeding women

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Bifidobacterium lactis HN019
Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
Bifidobacterium lactis HN019
Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
Placebo
Placebo, once a day for 14 days

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Fonterra Research Centre Danisco, Sprim Advanced Life Sciences

Outcome

Type Measure Description Time frame Safety issue
Primary Colonic transit time 14 days No
Secondary Gastrointestinal symptoms 14 days No
See also
  Status Clinical Trial Phase
Completed NCT05831527 - An Exploratory Investigation of a Supplement to Promote Gut Health N/A
Completed NCT03659747 - Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Fat-free Milk N/A
Recruiting NCT05972291 - Mechanisms of Gulf War Illness N/A
Completed NCT02054455 - Proton Pump Inhibitors and Gastrointestinal Symptoms Phase 4
Completed NCT03959722 - The Effect of Probiotics on GI Symptoms N/A
Recruiting NCT03514784 - Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder Phase 1/Phase 2
Completed NCT01927900 - The Effects Of HMO On The Faecal Microbiota And On Gastrointestinal Symptoms In Healthy Volunteers N/A
Recruiting NCT04919265 - Mother-Infant Cohort Study in Malaysia and China
Completed NCT00574197 - Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients Phase 4
Recruiting NCT03403387 - Effects of GlutenShield, a Prebiotic, Probiotic, and Enzyme Supplement, on the Gut Microbiome of Adults With GI Symptoms N/A
Completed NCT01964599 - Potato Fiber and Gastrointestinal Function: Phase 3 N/A
Recruiting NCT06248177 - Probiotic Effect on Gastrointestinal Symptoms (FLORABIOTIC REFUERZO). N/A
Withdrawn NCT04228003 - Pendulum D2D Glucose Control for Adults With Type 2 Diabetes N/A
Completed NCT03714464 - Effect of Physical Form of Apples on Gastrointestinal Function and Satiety: a MRI Study N/A
Active, not recruiting NCT03696953 - The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization. Phase 2
Completed NCT02277431 - Probiotic Supplementation Among Adults With Recurrent Gastrointestinal Symptoms Phase 2/Phase 3
Completed NCT00677378 - Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain N/A
Completed NCT03685552 - Safety Evaluation of a Diet and Nutritional Supplementation Program- Purify 2.0 N/A
Completed NCT01184456 - A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System Phase 2
Completed NCT01116388 - A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders N/A